Ocular Therapeutix (OCUL) Operating Leases (2019 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Operating Leases of $3.5 million for Q2 2026, down 21.37% year-over-year from $4.4 million in Q2 2025, and down 18.06% on a QoQ basis from $4.2 million in Q1 2026.
Ocular Therapeutix (OCUL) Operating Leases (2019 - 2026) Analysis & Trends
Ocular Therapeutix has reported Operating Leases for 8 years, with the latest figure at $3.5 million in Q2 2026.
- Operating Leases for Q2 2026 came in at $3.5 million, down 21.37% year-over-year; the trailing twelve-month figure through Jun 2026 was $3.5 million (down 21.37% YoY), and the FY2025 annual result was $2.8 million, down 47.33% from the prior year.
- Operating Leases retreated to $3.5 million in Q2 2026, from $4.2 million in the prior quarter.
- Over five years, Operating Leases peaked at $8.7 million in Q4 2022 and troughed at $2.8 million in Q4 2025.
- A 5-year average of $5.6 million and a median of $5.4 million in 2022 frame the typical range for Operating Leases.
- The widest annual swing landed in 2023, when Operating Leases surged 57.29%; it then slumped 47.33% in 2025.
- A 5-year view of Operating Leases shows it stood at $8.7 million in 2022, then fell by 20.74% to $6.9 million in 2023, then decreased by 22.29% to $5.3 million in 2024, then slumped by 47.33% to $2.8 million in 2025, then climbed by 23.13% to $3.5 million in 2026.
- Per Business Quant data, the three most recent Operating Leases figures were $3.5 million in Q2 2026, $4.2 million in Q1 2026, and $2.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.47 Mn |
| Mar 31, 2026 | 4.23 Mn |
| Dec 31, 2025 | 2.82 Mn |
| Sep 30, 2025 | 3.63 Mn |
| Jun 30, 2025 | 4.41 Mn |
| Mar 31, 2025 | 4.87 Mn |
| Dec 31, 2024 | 5.35 Mn |
| Sep 30, 2024 | 5.59 Mn |
| Jun 30, 2024 | 6.10 Mn |
| Mar 31, 2024 | 6.41 Mn |
| Dec 31, 2023 | 6.88 Mn |
| Sep 30, 2023 | 7.25 Mn |
| Jun 30, 2023 | 7.69 Mn |
| Mar 31, 2023 | 8.11 Mn |
| Dec 31, 2022 | 8.68 Mn |
| Sep 30, 2022 | 4.61 Mn |
| Jun 30, 2022 | 5.00 Mn |
| Mar 31, 2022 | 5.47 Mn |
| Dec 31, 2021 | 5.92 Mn |
| Sep 30, 2021 | 6.36 Mn |